Cargando…
Non-tuberculous mycobacteria lung disease due to Mycobacterium chimaera in a 67-year-old man treated with immune checkpoint inhibitors for lung adenocarcinoma: infection due to dysregulated immunity?
Immune checkpoint inhibitors (ICIs) are drugs growingly employed in cancer immunotherapy which have significantly improved the prognosis of several tumours. ICIs act by restoring the “exhausted” immune system and increasing the number of T cells active against pathogens losing tolerogenic signalling...
Autores principales: | Azzarà, Cecilia, Lombardi, Andrea, Gramegna, Andrea, Ori, Margherita, Gori, Andrea, Blasi, Francesco, Bandera, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476418/ https://www.ncbi.nlm.nih.gov/pubmed/37667178 http://dx.doi.org/10.1186/s12879-023-08537-w |
Ejemplares similares
-
Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review
por: Gramegna, Andrea, et al.
Publicado: (2022) -
Nontuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review
por: Lombardi, Andrea, et al.
Publicado: (2022) -
Immunological Markers of Lung Disease Due to Non-Tuberculous Mycobacteria
por: Lim, Andrew, et al.
Publicado: (2010) -
Surgical Site Infections due to Non-Tuberculous Mycobacteria
por: Yadav, Rohit Prasad, et al.
Publicado: (2018) -
Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review
por: Youssefnia, Artmis, et al.
Publicado: (2022)